Repeated intravenous injection of recombinant FVIII protein can prevent bleeding events, but alternative treatments could potentially improve patients' quality of life; therefore, hemophilia A is an attractive target disease for the application of gene therapy. The gene discussed is F8; the disease is hemophilia A.